Natera ( (NTRA) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Natera (NTRA) shares are climbing as investors react to strong company-specific news, including upbeat clinical results from the SINERGY head and neck cancer trial and new Signatera bladder cancer data unveiled at the ASCO GU Symposium. These developments reinforced management’s confidence in its oncology and MRD franchises, signaling robust growth ahead.
The rally also follows a recent analyst upgrade to Buy from Wall Street Zen, which boosted sentiment after Natera’s blockbuster fourth-quarter 2025 earnings beat. The positive read-through for its long-term outlook helped support the company’s 2026 revenue guidance of $2.62–$2.70 billion, encouraging more bullish price targets from the Street.
More about Natera
YTD Price Performance: -18.00%
Average Trading Volume: 1,173,335
Technical Sentiment Signal: Buy
Current Market Cap: $26.62B
For further insights into NTRA stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.